Stephen Graham concentrates in the areas of private and public mergers and acquisitions, public offerings, private placements and corporate governance matters, including advising boards of directors and audit, compensation and nominating/corporate governance committees, preparation and filing of periodic SEC reports and other securities law compliance, including Sarbanes-Oxley Act matters and disclosure issues with respect to Rule 10b-5 and Regulation FD.
His diverse practice is focused on the representation of emerging and established high-growth companies, essentially serving as an extension of the senior management teams and boards of directors. Stephen has represented companies and investment banks in numerous initial public offerings, a wide variety of merger and acquisition transactions, and private offerings of debt and equity.
Stephen has been recognized by Chambers USA as one of the top corporate and M&A lawyers in Washington. He is also a “Super Lawyer” award recipient (2000–2020), is listed in Who’s Who in America by Marquis Biographical Reference and has been recognized by The Best Lawyers in America for his work in biotechnology and life sciences, corporate law and M&A Law. Stephen is also a member of the political science honorary, Pi Sigma Alpha.
In 2019, Stephen was appointed to the Securities and Exchange Commission’s Advisory Committee on Small Business Capital Formation. In 2011, Stephen was appointed co-chairperson of the Securities and Exchange Commission’s Advisory Committee on Small and Emerging Companies and served in that position until fall of 2017. In 2015, he was named “one of the 19 most influential people in D.C. who can affect your small business” by The Washington Post for his role with the SEC. In 2019, Stephen was appointed to the Board of Directors of Washington Federal Bank, serving as chair of the Regulatory Compliance Committee as well as a member of the Audit and Corporate Governance Committees. Stephen is a member of the Yale Law School Association Executive Committee. He is active in community affairs, currently serving on the Board of Directors of the Fred Hutchinson Cancer Research Center, the Institute for Systems Biology, and the National Board of Friends of the Children.
Represented the following corporations until their acquisition:
- Amnis Corporation
- Corixa Corporaiton
- Corus Pharma
- ICOS Corporation
- Immunex Corporation
- WatchGuard Technologies
- Allen Institute for Brain Science
- Avalyn Pharma
- Mozart Therapeutics
- Oncology Impact Partners
- Sierra Oncology
- Sound Pharmaceuticals
Education & Admissions
J.D., Yale Law School
B.S., Iowa State University
Admitted to practice in Washington